Mutations in mitochondrial ferredoxin FDX2 suppress frataxin deficiency

Area of Science:

• Mitochondrial biology
• Genetics
• Neurodegenerative diseases

Background:

• Frataxin is essential for mitochondrial iron-sulfur (Fe-S) cluster biosynthesis and activates NFS1.
• Loss of frataxin causes Friedreich's ataxia, an inherited neurodegenerative disorder.
• Cellular tolerance to frataxin loss is oxygen-tension dependent.

Purpose of the Study:

• To identify genetic suppressors that bypass the requirement for frataxin in C. elegans.
• To investigate the molecular mechanisms by which these suppressors restore Fe-S cluster levels.
• To evaluate the therapeutic potential of modulating frataxin and FDX2 levels in Friedreich's ataxia models.

Main Methods:

• Genome-scale forward genetic screen in C. elegans under varying oxygen tensions.
• Genetic analysis of suppressor mutations in ferredoxin FDX2 and cysteine desulfurase NFS1.
• Biochemical assays to measure Fe-S cluster levels and NFS1 activity in vitro and in cell culture.
• Testing the effect of FDX2 reduction in C. elegans and a mouse model of Friedreich's ataxia.

Main Results:

• Suppressor mutations in FDX2 and NFS1 enhance Fe-S cluster synthesis without frataxin.
• These mutations alter the FDX2-NFS1 binding interface, boosting activity.
• Excess FDX2 inhibits NFS1 activity, while partial FDX2 knockdown ameliorates frataxin deficiency phenotypes.

Conclusions:

• Frataxin and FDX2 compete for binding to NFS1.
• Restoring the stoichiometric balance between frataxin and FDX2 is critical for Fe-S cluster biogenesis.
• Partial FDX2 knockdown represents a potential therapeutic strategy for Friedreich's ataxia.